Study identifier:D5890L00012
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Real Life Effectiveness in Asthma of Symbicort Single Inhaler Therapy
asthma
Phase 3
No
Budesonide/formoterol
All
550
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to determine whether patients with asthma are better able to manage and control their symptoms by using one inhaler daily that both prevents as well as treats the symptoms of an asthma exacerbation.
Location
Location
Airdrie, Lanarkshire, United Kingdom
Location
Ashford, United Kingdom
Location
Atherstone, United Kingdom
Location
Ayrshire, United Kingdom
Location
Barry, South Glamorgan, United Kingdom
Location
Bath, United Kingdom
Location
Blackpool, United Kingdom
Location
Bolton, United Kingdom
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.